Form 4: Dyne Therapeutics Director Reports Stock Sale

Director Jason P. Rhodes reported the sale of Dyne Therapeutics common stock held by affiliated investment funds.

Summary

• Director Jason P. Rhodes reported the sale of 227,264 shares of Dyne Therapeutics common stock on April 28, 2026.
• The transactions were executed via a Rule 10b5-1 trading plan adopted on March 19, 2026.
• Shares were sold at weighted average prices of $18.38 and $19.00 per share.
• The shares sold were held indirectly by various Atlas Venture funds, including Atlas Venture Opportunity Fund II, L.P. and Atlas Venture Fund XI, L.P.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while insider selling can be perceived negatively, the use of a pre-planned 10b5-1 program suggests routine portfolio management by a venture capital firm.

Positives

• Transactions were conducted under a pre-established Rule 10b5-1 trading plan, indicating a systematic rather than reactive divestment strategy.

Negatives

• Significant volume of shares (227,264) divested by a director-affiliated entity.

Risks

• Potential market perception of insider selling by a director-affiliated entity.

Future Outlook

No specific forward-looking guidance provided; the filing relates strictly to historical insider transaction reporting.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice for venture capital firms managing liquidity for their limited partners and does not necessarily reflect a change in the director's outlook on the company's fundamental prospects.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to sell shares while avoiding potential accusations of trading on material non-public information.

Related Party Transactions

• The reporting person is a member of the general partner entities for several Atlas Venture funds that hold Dyne Therapeutics stock.

Stakeholder Impact

• Shareholders may observe minor downward pressure on stock price due to the volume of shares sold.

Next Steps

• Continued monitoring of future Form 4 filings for further divestment activity by Atlas Venture-affiliated entities.

Key Dates

Keywords

Dyne Therapeutics, DYN, Insider Trading, Form 4, Atlas Venture, Biotech, Stock Sale